St 1006

The following histamine receptor ligands were used in this study: Histamine (ALK-Abello, Madrid, Spain) as agonist for all histamine receptors; 2-pyridylethylamine (Tocris Bioscience, Bristol, UK) as selective H1R agonist; amthamine (Tocris Bioscience, Bristol, UK) as selective H2R agonist; ST-1006 (Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University, Duesseldorf, Germany) as H4R agonist [21 (link)]; ranitidine (Sigma Aldrich, Deisenhofen, Germany) as selective H2R antagonist. JNJ7777120 (Sigma Aldrich, Deisenhofen, Germany) as selective H4R antagonist. All histamine receptor ligands were used at a concentration of 10 µM. In extensive previous studies we could show that the concentration of 10 µM is optimal to demonstrate and reproduce robust histamine receptor ligand mediated effects [22 (link)].

The following Histamine receptor ligands were used in this study: Histamine (ALK-Abello, Madrid, Spain) as agonist for all Histamine receptors; 2-pyridylethylamine (Tocris Bioscience, Bristol, UK) as selective H1R agonist; amthamine (Tocris Bioscience, Bristol, UK) as selective H2R agonist; H2R and H4R agonist 4-methylHistamine (4MH) (Tocris Bioscience, Bristol, UK); ST-1006 as selective H4R agonist [45 (link)] (Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University, Duesseldorf, Germany); ranitidine (Sigma Aldrich, Deisenhofen, Germany) as selective H2R antagonist; JNJ7777120 as selective H4R antagonist (Sigma Aldrich, Deisenhofen, Germany); all Histamine receptor ligands were used at a concentration of 10 µM. In extensive previous studies we could show that the concentration of 10 µM is optimal to demonstrate and reproduce robust Histamine-receptor ligand-mediated effects [46 (link)].